
Alexion Pharmaceuticals, Inc. ALXN
Alexion Pharmaceuticals, Inc. Gross Profit 2011-2026 | ALXN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Alexion Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 5.52 B | 4.6 B | 3.76 B | 3.1 B | 2.83 B | 2.37 B | 2.06 B | 1.37 B | 1.06 B | 690 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.52 B | 690 M | 2.73 B |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Assembly Biosciences
ASMB
|
79.1 K | $ 30.08 | 5.69 % | $ 337 M | ||
|
Ascendis Pharma A/S
ASND
|
625 M | $ 223.99 | 0.95 % | $ 5 B | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
Gilead Sciences
GILD
|
17.8 B | $ 138.83 | 1.18 % | $ 173 B | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
Grifols, S.A.
GRFS
|
2.79 B | $ 7.75 | 2.24 % | $ 6.83 B | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
Compugen Ltd.
CGEN
|
63.5 M | $ 2.14 | 2.39 % | $ 200 M | ||
|
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | ||
|
BioDelivery Sciences International
BDSI
|
14 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B | ||
|
Harmony Biosciences Holdings
HRMY
|
670 M | $ 28.15 | 1.55 % | $ 1.62 B | ||
|
Heron Therapeutics
HRTX
|
114 M | $ 0.8 | 3.3 % | $ 133 M | ||
|
ChemoCentryx
CCXI
|
64.9 M | - | - | $ 3.74 B | ||
|
Coherus BioSciences
CHRS
|
339 M | $ 1.57 | 2.96 % | $ 184 M | ||
|
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
Incyte Corporation
INCY
|
2.04 B | $ 92.2 | 1.56 % | $ 18 B | ||
|
InMed Pharmaceuticals
INM
|
1.4 M | $ 0.79 | -3.39 % | $ 1.93 M | ||
|
INmune Bio
INMB
|
-10.9 K | $ 1.17 | - | $ 21 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-40.6 M | $ 4.51 | 6.37 % | $ 748 M |